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Abstract
Background: We compared imipenem, meropenem and cefoperazone-sulbactam against hospital
originated A. baumannii strains in terms of bactericidal efficacy and selection of resistant mutants
during treatment in a rat thigh abscess model.
Methods: A total of 18 strains were inoculated in 54 animals (one strain for three animals).
Randomly selected 10 among these 18 strains were inoculated in another 10 rats as the control
group. Imipenem, meropenem and cefoperazone-sulbactam were the antibiotics compared. After
four days of treatment, Wistar albino rats (200 to 250 g) were sacrificed and the abscess materials
were processed for mean colony counts and for the presence of resistant mutants.
Results: The mean CFUs per gram (mean ± (std. deviation) [×104]) of the abscess were: 9,14
(25,24), 2,11 (3,78), 1,20 (1,70) in the imipenem (n = 17), meropenem (n = 18) and cefoperazone-
sulbactam (n = 17) groups, respectively. The differences were not significant. On the other hand,
no resistant mutant was detected in abscess materials.
Conclusion: This study indicated; first, cefoperazone-sulbactam is comparable to carbapenems in
bactericidal efficacy in this particular abscess model and second, emergence of resistance due to
spontaneous mutations is not at least a frequent phenomenon among A. baumannii.
Background
Acinetobacter species are associated with fatal infections in
hospitals, particularly in intensive care units [1]. Severe
underlying conditions like head trauma or head surgery
that cause gross aspiration are major risk factors for Aci-
netobacter infections [2,3]. The relation between Acineto-
bacter spp and an ominous outcome do not, however,
solely depend on the fact that the members of this genus
tend to cause infections in patients with severe underlying
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conditions. Another determining feature is these bacteria
often appear as multiply resistant to antibiotics [4].
Multiple resistance in Acinetobacter is believed -in most
instances- to be related to the abnormal expression of
chromosomally encoded, inherited mechanisms, like
porins, penicillin bounding proteins and chromosomal
beta-lactamases [5-8].
Resistance to beta-lactams due to altered intrinsic mecha-
nisms is not unique to Acinetobacter. Down regulated
porins co-operate with over expressed chromosomal beta-
lactamases and confer resistance to beta-lactams in some
other bacteria, as well. Pseudomonas  aeruginosa and
Enterobacter cloacae are well known examples [9].
Normally, in resting conditions, these intrinsic mecha-
nisms are under strict control in P. aeruginosa and  E.
cloacae. During replication, certain mutations push these
systems out of control as to give a resistant phenotype to
the mutants. In the presence of antibiotics these highly
resistant mutants are selected. This phenomenon is called
"emergence of resistance during antibiotic treatment",
which is of great concern in medical practice [10].
Since,  Acinetobacter  species bear similar systems; emer-
gence of resistance during treatment might be a significant
problem for this genus as well. As soon as we know, how-
ever, "emergence of resistance during treatment" has
never been tested in Acinetobacter in vivo conditions.
Here, we compared three most effective antibiotics against
Acinetobacterbaumannii  in a rat thigh abscess model in
terms of bactericidal efficacy and selection of resistance.
Methods
Bacterial strains
To ensure the clonal variability, we obtained a total of 18
A. baumannii strains from four university hospitals of dif-
ferent regions. Strains were susceptible to those studied
antibiotics. MICs were obtained buy E-test method. The
MICs of the strains ranged as for imipenem 0.25 to 1 mg/
L, meropenem 0.03 to 4 mg/L and cefoperazone-sul-
bactam 1 to 8 mg/L.
In our institute, we first re-identified the strains by classi-
cal methods. Later, glucose non-fermenting, oxidase neg-
ative, non-motile isolates those able to grow at 44°C were
further identified by Sceptor System non-fermenter ID
panel (Becton Dickinson Diagnostic Instrument Systems,
USA).
Animal model
Male Wistar albino rats of 200 to 250 g in weight were
inoculated by 6 log 10 colony-forming units (CFUs) of the
test strain in one thigh. The method has been explained in
details elsewhere [11]. Briefly, fresh overnight broth cul-
tures of the strains were adjusted to 8 log 10 CFUs per ml
and three Whatman disks per strain were saturated each
by 10 µl with the adjusted broth culture.
Following local ketamine and xylazine infusion approxi-
mately one cm incision were made in the medial side of
right thighs of the rats. Whatman disks -one per animal-
were implanted deep in the muscles and later the skin
closed by metal clips. Antibiotics were applied by intra-
peritoneal route two hours after the inoculation. Conse-
quently, 54 animals were implanted with that of 18 A.
baumannii strains. An additional 10 rats, as the control
group, were implanted with randomly selected strains
among these 18 strains. The control group did not receive
antibiotic.
Antibiotic daily amounts and dosing were as follows: imi-
penem, 120 mg/kg every 8 h; meropenem 120 mg/kg
every 8 h; cefoperazone 400 mg/kg/day (with a fixed ratio
of [1:1] cefoperazone to sulbactam).
Antibiotic bioassay, Colony count and resistance selection
On the fourth day, 30 minutes after the last dose of the
antibiotic infusion, animals were sacrificed. Following
this, without any delay, 0.5 to one ml blood was aspirated
by appropriate needle from cardiac compartments. Sera
was separated and stored at minus 80°C until the antibi-
otic bioassay test.
The abscess were totally excised with its capsule and put in
pre-weighted sterile tubes with one ml Mueller-Hinton
(MH) broth, all in aseptic conditions. After homogeniza-
tion of the abscess by sterile glass rods, 10 and 100 µl of
these suspensions were inoculated on two separate Mac-
Conkey agar plates for colony count and 100 µl each on
three MH agar plates supplemented with 4 mg/L imi-
penem, 4 mg/L meropenem or 16 mg/L cefoperazone-sul-
bactam. Before evaluation, plates were over-night
incubated at 37°C in an incubator. Colonies grown on the
antibiotic supplemented media were re-tested by agar disk
diffusion for resistance to these antibiotics.
Antibiotic bioassays were performed on MH agar plates.
MH agars were supplemented with 6 to 7 log 10 CFUs of
E. coli ATCC 25922 at 55°C, just before pouring to the
plates. Afterwards, under strict sterile conditions, five
wells (2–3 mm diameter) per plate were made and each
well was inoculated by 20 µl of serum. Plates were evalu-
ated after an over-night incubation at 37°C.Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/2
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Statistical analysis
Statistical analysis was performed by a software package
SPSS (ver 7.5). Significance was defined as p < 0.05. Con-
tinuous variables were compared by ANOVA test.
Results
Abscess from 17 rats in each the imipenem and cefopera-
zone-sulbactam groups and from 18 rats in the mero-
penem group were eligible. Results from two rats, one in
the imipenem and one in the meropenem groups were
excluded because of the technical problems during antibi-
otic bioassay test.
All of the control animals were alive and the abscesses
were well developed. The CFUs per 100 µl of samples in
the control group were higher than the countable limits.
Antibiotic bioassays, abscess weights and CFUs per 100 µl
of samples were shown in the table. Standard deviations
in the treated group are apparently lower than the control
group. Hence, it is not wrong to say that the treated groups
have significantly lower bacterial counts. On the other
hand, there was no statistical significance either between
the weights of abscess materials or between mean CFUs
obtained from 100 µl of these samples. The mean CFUs
per gram (×104) of the abscess were: 9,14 (± 25,24) in the
imipenem group, 2,11 (± 3,78) in the meropenem group
and 1,20 (± 1,70) in the cefoperazone-sulbactam group.
Although the mean CFUs per gram of abscess was lower in
the cefoperazone-sulbactam group this was not signifi-
cant. Antibiotic bioassays were also similar and adequate
for all the groups. Important is, in this study we were not
able to detect any resistant isolate in the abscess materials.
Discussion
Acinetobacter spp has a tendency to develop resistance to
multiple antibiotics [12]. The co-operation of down regu-
lated outer membrane porins with chromosomal beta-
lactamases and/or PBPs have been already proposed to
explain the multiple resistance in Acinetobacter [7,8,13].
In Turkish hospitals, resistance to expanded-spectrum
beta-lactams among Acinetobacter is not less than 80% and
only half of this resistance has been shown to be related
to extended-spectrum beta-lactamases [14,15]. Although
the resistance mechanisms in the remaining half have not
been studied, it would not be unwise to accuse above
mentioned intrinsic mechanisms here, as well.
Here, we studied among A. baumannii strains from differ-
ent regions of Turkey. We selected A. baumannii, because
this species is proposed as more common in nosocomial
infections and probably more virulent relative to the other
members of the genus [2,12]. On the other hand, the
strains were selected from different regions to ensure the
clonal variability. In these conditions and up to four days
we could not detect any resistant mutant under the treat-
ment of commonly used three antibiotics among these A.
baumannii isolates. Nevertheless, resistance might emerge
with prolonged time of exposure to these antibiotics [16].
Conclusions
Results of this study convince to think that "emergence of
resistance during treatment" with the above antibiotics is
not at least a frequent phenomenon for A. baumannii and
cefoperazone-sulbactam is as effective as carbapenems in
the abscess model.
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Table 1: Comparison of variables between groups
mean ± (std. dev)
Imipenem (n = 17) Meropenem (n = 18) Cefo-sulb1 (n = 17) Control (n = 10) p2
CFUs3 166.71 (285.87) 109.00 (165.38) 156.41 (229.48) > 1000 - 0.73
Abscess 
Weight 
(grams)
0.071 (0.049) 0.125 (0.253) 0.138 (0.037) 0.120 (0.058) 0.41
CFUs/gm 
abscess 
(×103)
9,14 (25,24) 2,11 (3,78) 1,20 (1,70) >100 0.23
Bioassay4 19.88 (2.45) 19.33 (2.63) 20.76 (4.42) 0 - 0.43
1 Cefo-sulb, cefoperazone-sulbactam 2 p value obtained by ANOVA test. Comparisons were between treatment groups. 3 CFUs; colony forming 
units in 100 µl of sample 4 Bioassay: zone diameters in mmPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/2
Page 5 of 5
(page number not for citation purposes)
Acknowledgements
We thank to KOU Tip Fakultesi research unit DETAB for supporting this 
study.
References
1. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C:
Nosocomial pneumonia in ventilated patients: a cohort
study evaluating attributable mortality and hospital stay. Am
J Med 1993, 94:281-288.
2. Akca O, Koltka K, Uzel S, Cakar N, Pembeci K, Sayan MA, Tutuncu
AS, Karakas SE, Calangu S, Ozkan T, Esen F, Telci L, Sessler DI, Akpir
K: Risk factors for early-onset, ventilator-associated pneu-
monia in critical care patients: selected multiresistant versus
nonresistant bacteria. Anesthesiology 2000, 93:638-645.
3. Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J: Risk fac-
tors for infection by Acinetobacter baumannii in intubated
patients with nosocomial pneumonia.  Chest 1997,
112:1050-1054.
4. Gomez J, Simarro E, Banos V, Requena L, Ruiz J, Garcia F, Canteras
M, Valdes M: Six-year prospective study of risk and prognostic
factors in patients with nosocomial sepsis caused by Acineto-
bacter baumannii. Eur J Clin Microbiol Infect Dis 1999, 18:358-361.
5. Hancock RE: Resistance mechanisms in Pseudomonas aerugi-
nosa and other nonfermentative gram-negative bacteria. Clin
Infect Dis 1998, 27 Suppl 1:S93-9.
6. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J:
Characterization of a nosocomial outbreak caused by a mul-
tiresistant Acinetobacter baumannii strain with a carbap-
enem-hydrolyzing enzyme: high-level carbapenem
resistance in A. baumannii is not due solely to the presence
of beta-lactamases. J Clin Microbiol 2000, 38:3299-3305.
7. Perilli M, Felici A, Oratore A, Cornaglia G, Bonfiglio G, Rossolini GM,
Amicosante G: Characterization of the chromosomal cepha-
losporinases produced by Acinetobacter lwoffii and Acineto-
bacter baumannii clinical isolates. Antimicrob Agents Chemother
1996, 40:715-719.
8. Obara M, Nakae T: Mechanisms of resistance to beta-lactam
antibiotics in Acinetobacter calcoaceticus.  J Antimicrob
Chemother 1991, 28:791-800.
9. Livermore DM: Interplay of impermeability and chromosomal
beta-lactamase activity in imipenem-resistant Pseudomonas
aeruginosa. Antimicrob Agents Chemother 1992, 36:2046-2048.
10. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP,
Ramphal R, Wagener MM, Miyashiro DK, Yu VL: Enterobacter bac-
teremia: clinical features and emergence of antibiotic resist-
ance during therapy. Ann Intern Med 1991, 115:585-590.
11. Karadenizli A, Mutlu B, Okay E, Kolayli F, Vahaboglu H: Piperacillin
with and without tazobactam against extended-spectrum
beta-lactamase-producing Pseudomonas aeruginosa in a rat
thigh abscess model. Chemotherapy 2001, 47:292-296.
12. Bergogne-Berezin E, Towner KJ: Acinetobacter spp. as nosoco-
mial pathogens: microbiological, clinical, and epidemiologi-
cal features. Clin Microbiol Rev 1996, 9:148-165.
13. Sato K, Nakae T: Outer membrane permeability of Acineto-
bacter calcoaceticus and its implication in antibiotic
resistance. J Antimicrob Chemother 1991, 28:35-45.
14. Aksaray S, DokuzoGuz B, Guvener E, Yucesoy M, Yulug N, Kocagoz
S, Unal S, Cetin S, Calangu S, Gunaydin M, Leblebicioglu H, Esen S,
Bayar B, Willke A, Findik D, Tuncer I, Baysal B, Gunseren F,
Mamikoglu L: Surveillance of antimicrobial resistance among
gram-negative isolates from intensive care units in eight hos-
pitals in Turkey. J Antimicrob Chemother 2000, 45:695-699.
15. Vahaboglu H, Ozturk R, Aygun G, Coskunkan F, Yaman A, Kaygusuz
A, Leblebicioglu H, Balik I, Aydin K, Otkun M: Widespread detec-
tion of PER-1-type extended-spectrum beta-lactamases
among nosocomial Acinetobacter and Pseudomonas aerugi-
nosa isolates in Turkey: a nationwide multicenter study. Anti-
microb Agents Chemother 1997, 41:2265-2269.
16. Wolff M, Joly-Guillou ML, Farinotti R, Carbon C: In vivo efficacies
of combinations of beta-lactams, beta-lactamase inhibitors,
and rifampin against Acinetobacter baumannii in a mouse
pneumonia model.  Antimicrob Agents Chemother 1999,
43:1406-1411.